Brian advises clients on complex life sciences patent litigations as well as related regulatory, antitrust, and trade secret issues. He has counseled numerous biotechnology and pharmaceutical companies in developing effective patent litigation strategies for a wide array of products. Brian has also lead patent litigations involving small molecule drugs, biological products, medical devices, and nanofluidic devices.
Prior to joining the firm, Brian worked for over a decade as a pharmaceutical research and development scientist. During his pharmaceutical career, Brian conducted original research and was responsible for several research groups that focused on products for a variety of medical conditions, including: asthma, allergies, cardiovascular, anti-inflammation, hematology, and oncology. His practical industry experience is indispensable to clients who seek Brian’s assessment as part of their intellectual property strategy.
Brian’s practice also includes counsels clients regarding patent-portfolio evaluation and analysis, the patentability of inventions, freedom-to-operate new technologies, and FDA issues.
- AbCellera Biologics, Inc.
- Axsome Therapeutics, Inc.
- Celgene Corporation
- Janssen Pharmaceuticals, Inc.
- Jazz Pharmaceuticals, Inc.
- Medytox, Inc.
- Mitsubishi Tanabe Pharma
- Takeda Pharmaceuticals USA, Inc.
- Veloxis Pharmaceuticals, Inc.
- Representing Axsome Therapeutics in multiple Hatch-Waxman actions relating to its Sunosi® (solriamfetol) drug product.
- Representing Veloxis Pharmaceuticals in Hatch-Waxman actions relating to its Envarsus XR® (tacrolimus) drug product.
- Representing Medytox in ITC investigation related to botulinum toxin products.
- Representing Jazz Pharmaceuticals in brand versus brand patent infringement and trade secret matters.
- Represented Takeda Pharmaceuticals in Hatch-Waxman actions relating to its Iclusig® (ponatinib) drug product. The actions settled favorably for Takeda.
- Represented Celgene Corporation in more than a dozen Hatch-Waxman actions relating to its Revlimid® (lenalidomide) drug product. These actions settled favorably for Celgene.
- Represented Janssen Pharmaceutical and Mitsubishi Tanabe Pharma in a fourteen-defendant Hatch-Waxman litigation relating to Janssen’s Invokana® (canagliflozin)/Invokamet®/Invokamet XR® drug products. These actions settled favorably for Janssen and MTPC.
- Represented Celgene Corporation in multiple Hatch-Waxman actions relating to its Pomalyst® (pomalidomide) drug product. These actions settled favorably for Celgene.
- Represented Jazz Pharmaceutics in multiple Hatch-Waxman actions relating to its Xyrem® (sodium oxybate) drug product. These actions settled favorably for Jazz.
- Fordham University School of Law
(J.D., 2013) - Seton Hall University
(Ph.D., Chemistry, 2007) - Rutgers University
(B.S., Biochemistry, 1999)
- The State Bar of New Jersey
- The State Bar of New York
- United States District Court:
- District of New Jersey
- Southern District of New York
- Named a Rising Star by Super Lawyers, 2021-2023
- Ranked in Patexia ANDA Litigation Intelligence Report as one of the “Top Best Performing” and “Most Active” Attorneys, 2021-2023